Advances in aptamer technology for target-based drug discovery
Journal of Pharmaceutical Analysis · 2026-02 · 16 (2) · 101369
DOI: 10.1016/j.jpha.2025.101369 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmaceutical Analysis, 2026-02. Verfasst von Yingxian Cui und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Peking University.
Abstract (Originalsprache)
Aptamer therapeutics represent a class of target-based therapies that leverage their high specificity and affinity for diverse molecular targets. As single-stranded DNA or RNA oligonucleotides, aptamers offer advantages in therapeutic applications. A critical aspect of aptamer drug development is the selection process, which has seen significant advancements through various in vitro selection methods, including Systematic Evolution of Ligands by Exponential Enrichment and its emerging variations. Recent progress has also introduced functional screening strategies that directly identify pharmacologically active aptamers, accelerating drug discovery. The applications of aptamers in disease treatment are expanding across oncology, neurodegenerative disorders, infectious diseases and other diseases. Aptamers exhibit versatile mechanisms of action, including blocking interactions, recruiting protein machinery, and inhibiting target functions. By addressing key limitations and presenting future directions, this review provides a comprehensive perspective on the recent evolving landscape of aptamer technology and its transformative potential in modern medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Peking University
- Key Technologies Research and Development Program
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Cui, Y., Chen, Y., Zhang, Y., & Zhang, L. (2026). Advances in aptamer technology for target-based drug discovery. Journal of Pharmaceutical Analysis, 16(2), 101369. https://doi.org/10.1016/j.jpha.2025.101369
Vancouver
Cui Y, Chen Y, Zhang Y, Zhang L. Advances in aptamer technology for target-based drug discovery. Journal of Pharmaceutical Analysis. 2026;16(2):101369. doi:10.1016/j.jpha.2025.101369
BibTeX
@article{Cui2026,
author = {Cui, Yingxian and Chen, Yifan and Zhang, Youbo and Zhang, Liqin},
title = {Advances in aptamer technology for target-based drug discovery},
journal = {Journal of Pharmaceutical Analysis},
year = {2026},
volume = {16},
number = {2},
pages = {101369},
doi = {10.1016/j.jpha.2025.101369}
}
EUVIMED